Seven Life Tech Companies in iCarbonX's Digital Life Ecosystem File IPO Prospectuses

There is a problem with the methods for detecting the proteome:Due to its high complexity and difficulty, there is currently no efficient, accurate, and rapid technology available to measure it.Because, over time, the measurement of proteins in the human body varies under different disease conditions, andSomaLogicHigh-throughput, low-cost solutions are available.Capable ofMeasuring 5,000 of the approximately 20,000 proteins in the human body 。

Larry Gold, Founder and Chairman of SomaLogic

After 15 years of dedicated research, SomaLogic has developed SOMAscan®, a breakthrough proprietary technology for protein quantification.To provide researchers, patients, and clinicians with the key molecular information they need to monitor and manage lifelong health, including understanding disease onset and progression, as well as discovering and rapidly testing effective treatment regimens.

They tracked an individual for four years, digitizing their data through protein measurements. Of the proteins measured, approximately 900 remained unchanged, while the levels of the remaining proteins fluctuated up and down.Artificial intelligence is designed to analyze proteins that fluctuate across different time periods, as well as the correlation between their changes and individual disease states. This is why SomaLogic and iCarbonX have joined forces, aiming to expand protein testing to a population of one million. In the future, they plan to leverage AI engines to drive these big data insights, enabling the development of more customized products for personalized health management.

An example demonstrating how SomaLogic’s research supports personalized medicine: SomaLogic andof the Department of Cardiology at San Francisco College in CaliforniaDr. Peter collaborated on a small-scale clinical trial involving 1,000 patients with varying degrees of high-risk cardiovascular disease. All patients received standardized treatment in the United States, demonstrating significant therapeutic efficacy.

SomaLogic conducted an eight-year follow-up study, during which it was found that the likelihood of a second cardiovascular event varied significantly among patients with similar cardiovascular diseases. Some patients showed no difference from the general population after receiving treatment, while others had a relatively higher risk of recurrence.Therefore, they developed a method to screen nine blood proteins (CVD9) from 1,130 proteins, helping physicians identify cardiac patients at high risk of recurrence, thereby enabling these high-risk individuals to receive appropriate treatment and achieve better clinical outcomes.

To date, SomaLogic has measured 125,000 samples using the SOMAscan® platform.Going forward, SomaLogic and iCarbonX will establish a joint venture in China to provide the Chinese research and health applications industry with SOMAscan® proteomics testing technology, as well as the foundational protein data required to build a digital life ecosystem.

HealthTellDeveloped a series of Immunosignature™ technologies to help alliance members gain valuable insights into how individual immune systems respond to various medical conditions, behavioral habits, and environmental factors.

Bill Colston, CEO of HealthTell

The entire HealthTell process involves collecting a single drop of blood and applying it to a monitoring chip. The system detects antibodies present in the blood and performs comparative analysis against data in its database. Notably, the HealthTell database is built upon large-scale clinical trials. Different diseases trigger distinct immune responses, leading to variations in an individual’s antibody profile. By analyzing the composition of antibodies in the blood, HealthTell assesses an individual’s health status and provides diagnostic results for relevant diseases.

To achieve this goal, HealthTell has developed a miniature chip featuring over three million distinct probes to facilitate the detection and collection of relevant data. HealthTell manufactures this chip using a process analogous to Intel’s production of computer chips: while Intel arrays electronic components, HealthTell arrays biomolecules.。

This antibody detection chip has seen a significant reduction in cost, offering excellent cost-effectiveness and enabling large-scale mass production. This allows HealthTell to acquire extensive health information at a low cost.

Another application of this product is medication guidance.When collaborating with the world’s largest pharmaceutical institutions and participating in their drug research and development programs, one of the biggest questions for pharmaceutical companies is why some patients respond positively to medications while others do not. For instance, immune checkpoint inhibitors are highly effective anticancer drugs with minimal side effects, yet they are only effective in approximately 20% of the global population.

These pharmaceutical institutions are unaware of the specific reasons behind these results; HealthTell believes that part of the explanation lies in the human immune system.By analyzing it, you can not only determine which medications you need to take but also understand how your immune system will respond to the drug and what outcomes will result.

In addition, this technology can also be applied inDiagnosing Refractory Diseases and Evaluating Vaccine Efficacy。

PatientsLikeMeIt is the world’s first personalized social network for patients, offering a direct-to-consumer platform that integrates, analyzes, and presents individualized health information. To date, more than 500,000 people have been using PatientsLikeMe to digitize and share their disease experiences, thereby improving prognostic and treatment outcomes.

This is not merely a social platform for patients; in fact, it is the most critical platform for non-quantitative data, enabling the most direct and quantifiable informational processing of various bodily sensations.For example, issues such as pain, sleep disturbances, fatigue, and emotional problems.

Paul Wicks, Vice President of PatientsLikeMe

PatientsLikeMe assesses your mood—ranging from “very good,” “good,” “fair,” “poor,” to “very poor”—via email, its mobile app, and website. It then further refines the evaluation of health status based on patients’ quality-of-life feedback as well as their social, psychological, and physiological conditions.

Currently, more than 20 pharmaceutical companies, including AstraZeneca, Takeda, and Novartis, as well as government organizations such as the U.S. Food and Drug Administration (FDA), have established partnerships with PatientsLikeMe and are leveraging data to understand the states of living with disease and disease cure.

In the PatientsLikeMe system, every user can view other patients’ medical records, unlike traditional medical records that are accessible only to the patient and their physician. This enables patients to engage in collaborative discussions and identify optimal solutions to address their health concerns. Through peer communication and interaction, two-thirds of patients reported that using PatientsLikeMe improved their quality of life while managing their symptoms, and two-thirds found ways to mitigate side effects.

On January 5, 2017, PatientsLikeMe secured $100 million in financing from the iCarbonX ecosystem.

AOBiomeDeveloped the world’s first and top-tier probiotic therapy,Restoring Ammonia-Oxidizing Bacteria (AOB) in the Human Microbiome Through Microbiome Reconstruction Therapy to Improve Overall Health, Particularly Skin Condition。The company will provide the first commercialized application within the Digital Life Alliance.

Todd Krueger, President of AOBiome

AOBiome’s founder, David Whitlock, is a chemist from MIT. One day, while on a date, his companion noticed a horse rolling in the dirt and asked, “Why do you think horses do that?” In response, David conducted an experiment in which he cultured artificial sweat on soil from a Boston-area farm for three months.

He then applied the microbial community to his skin, and his health improved after application. He introduced it to others, who also reported feeling significantly healthier after applying it to their bodies. In this experiment, David did not shower; had he done so, he would not have experienced these benefits, as the chemicals mentioned earlier, such as laundry detergents, would directly kill the bacteria.

David discovered that the species was a milestone, named *Nitrosomonas eutropha* (a bacterium capable of oxidizing ammonia). In fact, every person in the world produces ammonia, and the human liver is responsible for clearing it; ammonia can be found everywhere in the world, and wherever ammonia is present, this bacterium—which thrives on ammonia—can also be found. However, even trace amounts of preservatives can eliminate these bacteria, and human hygiene products have wiped out this beneficial microorganism.

During the process of consuming ammonia, this bacterium produces only two byproducts: nitrite and nitric oxide. These are beneficial compounds with anti-infective properties. Consequently, AOBiome’s research has led to the development of a product derived from a mixture of sweat and soil, formulated as a fine spray that recolonizes the skin with ammonia-oxidizing bacteria upon application.

AOBiome has leveraged this technology to develop a product, which was distributed to over 40,000 consumers for trial use. The company received positive feedback via email, and the product has now entered the FDA clinical trial phase.

On January 5, 2017, AOBiome secured a $30 million investment from the iCarbonX ecosystem to support clinical research into its innovative “bacterial platform” therapies.

GALT(General Automation Lab Technologies) is dedicated to discovering, developing, and commercializing a new generation of high-throughput microbial monitoring and isolation products by integrating interdisciplinary breakthrough technologies. GALT Technologies will provide critical in-depth insights into the vast and complex human microbiome, enabling personalized assessment of microbes related to human health, while developing personalized therapeutic interventions to restore our microbiome to a state of optimal health.

Peter Christey, CEO and Founder of GALT

GALT’s technology involves cultivating microorganisms on high-density chips., thereby obtaining a digital snapshot of the microbiome, which then allows for further targeted cultivation and study of specific species of interest. A traditional petri dish typically yields around 50 data points related to microbial communities. In contrast, GALT’s technology can collect between 10,000 and 150 million distinct data points in a single experiment.

By analogy, the currently widely used petri dishes are akin to the first computer in 1946, while GALT’s technology is comparable to today’s microprocessors.

Through digital technologies, we can not only identify all existing microbial species but also gain insights into sub-communities and their obscure functions, as well as their complex, poorly understood superstructures. This means that we are now capable of understanding the human microbiome in a more systematic and refined manner.Then, appropriate preventive or therapeutic measures should be taken against the diseases they may cause.

Consider a simple example of antibiotic-associated diarrhea. The use of antibiotics delivers a devastating blow to the gut microbiota, allowing certain bacteria to proliferate rapidly and leading to diarrhea. Some individuals who take gastrointestinal medications long-term may suffer from diarrhea for decades.

Tianjin Qiangweite Biotechnology Co., Ltd., established in 2010, dedicated to the research and development as well as industrialization of enzyme preparations and high-end biological skincare products.

Zheng Chunyang, Chairman of Tianjin Strong Microbial Biotechnology Co., Ltd.

To advance its precision skincare initiative, Qiangweite Biotechnology has leveraged not only professional talent and advanced equipment but also assembled a comprehensive collection of representative products from all major global skincare brands. These products were evaluated across multiple dimensions, including cosmetic ingredients, relevant scientific literature, published cosmetic patents, and user feedback. Over one thousand products were selected for purchase and subjected to preliminary physicochemical analyses and expert assessments in the laboratory, from which more than one hundred representative products were ultimately chosen.

Subsequently, a systematic theoretical and experimental evaluation was conducted on more than 100 products. In particular, based on skincare ingredients, Qiangweite Biotechnology performed meticulous testing on the synergistic effects, antagonistic effects, and compatibility among individual ingredients. This process identified the strengths and weaknesses of each product. Building on these insights, the company developed its own proprietary products, accumulating a robust portfolio of mature formulations. Several of these products have been launched to the market with highly positive reception.

This is merely the first step in precision skincare. To further advance this initiative, Qiangweite Biotechnology conducted multi-omics testing. This involved collecting customer saliva samples for genetic analysis, stool samples for gut microbiome assessment, skin surface samples for microbial and sebum analysis, and urine samples for metabolomic profiling. Additionally, image analysis was used to evaluate customers' skin conditions, and behavioral data were collected via questionnaires. Finally, these diverse datasets were integrated for systematic utilization.

The company has currently launched eight products, namely facial cleansing massage cream, toner, serum, facial mask, lotion, and makeup base/primer. Among these, the serum is the core product, formulated by combining a basic serum with personalized serum prototypes based on the iCarbonX Beauty Algorithm.Therefore, the ultimate outcome is that each digital life form can receive its personalized digital skincare formula.

Israeli AI CompanyImaguIts core technology involves establishing digital human models through machine learning-based image recognition. As early as September 10, 2016, Imagu announced its integration into the iCarbonX ecosystem and the establishment of the iCarbonX Israel Artificial Intelligence R&D Center.

Leveraging its proprietary image processing technology, Imagu has developed three types of application devices to monitor patients, using the resulting data to train its algorithms:An app for tracking dietary activities, a smart wristband capable of detecting activity and sleep patterns, and a smart mirror.

The application of smart dietary solutions can generate personalized diet plans for individuals based on input from nutritional databases. Users can complete this customization process conveniently via their smartphones, with all data being recorded. This tool is extremely user-friendly: simply take a photo with your phone, and the system will perform deep learning analysis on it.The system can analyze what you have eaten, what you need to eat, and what dietary adjustments and changes you should make in the future, simply by examining an image.

The current features of this application also include tracking physical health status., users need only hold the camera, and the system can perform relevant analyses based on the captured video, such as assessing the user’s current pulse status and determining whether heart rate increases after exercise, functioning similarly to a health guide.

Additionally, this application can perform facial recognition and monitoring., as diet affects skin quality, Imagu aims to provide users with personalized improvement recommendations—such as dietary adjustments and optimal sleep duration—by tracking facial conditions, all achievable via smartphone.

Smart Mirror,Standing in front of the mirror, users can measure various physiological metrics in under ten seconds. The mirror provides highly accurate feedback on whether weight loss is needed and assesses the user’s body shape.

Smart Mirror

We can understand Miwo by likening it to a navigation map., when we enter a destination. The navigation system will recommend the optimal route and the estimated time of arrival, while online maps will inform us of traffic congestion locations, the length of congested segments, and the duration of delays. Similarly, when we use the Miwo platform, Miwo will recommend the optimal lifestyle based on the user’s individual profile, and indicate your health status, disease probability, and potential risks at different age stages if you adhere to this lifestyle.

Of course, if we strictly adhered to prescribed plans in our daily lives, it would be utterly monotonous; humans are inherently rebellious. For instance, I might drink a bit more today, and by the age of 30, with minimal physical activity leading to declined physiological functions, what can be done? There is no need for concern. Just as a navigation system recalibrates when we deviate from the planned route—providing a new itinerary along with updated distance and estimated time of arrival—Mi AI operates similarly. It adjusts its expectations based on users’ “non-compliant lifestyles,” making them aware of the potential consequences of their behaviors, while simultaneously formulating a revised health management plan for their use.